Cargando…

Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment

Background: Circulating tumor DNA (ctDNA) released from tumor cells carries the tumor-associated genetic and epigenetic characteristics of cancer patients. Next-generation sequencing (NGS) facilitates the application of ctDNA profiling for identification and monitoring of minimal residual disease (M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Linghui, Zhao, Houli, Shao, Yang, Chen, Xin, Hong, Ruimin, Wang, Linqin, Ni, Fang, Nagler, Arnon, Hu, Yongxian, Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364638/ https://www.ncbi.nlm.nih.gov/pubmed/34405005 http://dx.doi.org/10.7150/jca.60390

Ejemplares similares

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma
por: Hong, Ruimin, et al.
Publicado: (2021)

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Wang, Linqin, et al.
Publicado: (2021)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

COVID-19 in Hematologic Malignancies: Big Challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
por: Hu, Yongxian, et al.
Publicado: (2022)

Precision medicine: In need of guidance and surveillance
por: Lin, Jian-Zhen, et al.
Publicado: (2017)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
por: Hong, Ruimin, et al.
Publicado: (2021)

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Wang, Yiyun, et al.
Publicado: (2021)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020)

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021)

Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
por: Zhou, Linghui, et al.
Publicado: (2021)

EUPATI Guidance for Patient Involvement in Medicines Research and Development (R&D); Guidance for Pharmaceutical Industry-Led Medicines R&D
por: Warner, Kay, et al.
Publicado: (2018)

The effect of circulating miR-223 on surveillance of different cancers: a meta-analysis
por: Zhang, Yunfeng, et al.
Publicado: (2017)

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma
por: Messerli, Christian, et al.
Publicado: (2023)

Mix-and-diffuse serial synchrotron crystallography
por: Beyerlein, Kenneth R., et al.
Publicado: (2017)

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma
por: Zhang, Qiqi, et al.
Publicado: (2023)

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
por: Yang, Yingying, et al.
Publicado: (2018)

Chimeric LuxR Transcription Factors Rewire Natural Product Regulation
por: Mukherji, Ruchira, et al.
Publicado: (2020)

miR-4284 and miR-4484 as Putative Biomarkers for Diffuse Large B-Cell Lymphoma
por: Tamaddon, Gholamhossein, et al.
Publicado: (2016)

Circulating Exosomal MiR-107 Restrains Tumorigenesis in Diffuse Large B-Cell Lymphoma by Targeting 14-3-3η
por: Liu, Jiarui, et al.
Publicado: (2021)

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
por: Snyder, Sophie, et al.
Publicado: (2021)

Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
por: Sushentsev, Nikita, et al.
Publicado: (2022)

Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy
por: Feng, Jingjing, et al.
Publicado: (2022)

Evaluation of the Effects of R-CHOP Chemotherapy on Brain Glucose Metabolism in Patients with Diffuse Large B Cell Lymphoma: A Baseline, Interim, and End-of-Treatment PET/CT Study
por: Zhu, Haiyan, et al.
Publicado: (2022)

Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines
por: Koo, Sunwoo, et al.
Publicado: (2012)

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
por: Harvey, Kyra, et al.
Publicado: (2023)

Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma
por: Cui, Qingyan, et al.
Publicado: (2018)

NETest: serial liquid biopsies in gastroenteropancreatic NET surveillance
por: van Treijen, Mark J C, et al.
Publicado: (2022)

The chimeric GaaR-XlnR transcription factor induces pectinolytic activities in the presence of D-xylose in Aspergillus niger
por: Kun, Roland S., et al.
Publicado: (2021)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Feasibility of Quantitative Flow Ratio Virtual Stenting for Guidance of Serial Coronary Lesions Intervention
por: Guan, Shaofeng, et al.
Publicado: (2022)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

Serial Diffusion-Weighted Imaging in Transient Global Amnesia?
por: Onder, Halil
Publicado: (2018)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
por: Zhang, Yinqiang, et al.
Publicado: (2022)

A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC
por: Bemis, Thomas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d0j2uhuqheabte2mubpogcm71f